RxDoctor Payments Data

Victor Lambert, MD

Family Medicine · Manchester, GANPI 1154317790

Payments from drug & device makers

$1,564in general payments, 2019–2025

Across 74 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$738
  • Lilly USA, LLC$190
  • Novartis$189
  • Pfizer$103
  • Boehringer Ingelheim$86
  • Exact Sciences$58
  • plus $201 from 8 others

What the payments were for

  • Food & beverage$1,563100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,564 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$124,009
Medicare patients
231
Services billed
1,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban838$244,291
JardianceEmpagliflozin86$64,142
FarxigaDapagliflozin Propanediol135$62,790
OzempicSemaglutide55$60,376
RybelsusSemaglutide19$37,812
LinzessLinaclotide42$33,473
JanuviaSitagliptin Phosphate125$33,012
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$32,458
EntrestoSacubitril/Valsartan119$28,635
TrulicityDulaglutide39$28,125
XareltoRivaroxaban197$27,650
Invega SustennaPaliperidone Palmitate11$26,895
TradjentaLinagliptin63$25,204
Austedo XrDeutetrabenazine14$23,183
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$15,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$244,291838 claims
Novo NordiskOzempic, Rybelsus, Levemir, Tresiba$738$114,287165 claims
Boehringer IngelheimJardiance, Tradjenta$86$89,346149 claims
AstraZenecaFarxiga, Symbicort, Lokelma, Brilinta$33$80,586197 claims
MerckJanuvia$11$33,012125 claims
NovartisEntresto$189$28,635119 claims
Lilly USA, LLCTrulicity$190$28,12539 claims
Astellas Pharma US IncMyrbetriq$24$11,93053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Manchester

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →